Latest Breaking News On - Alnylam pharmaceuticals nasdaq - Page 8 : comparemela.com

Alnylam Pharmaceuticals, Inc : Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc : Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomAkshay desaiSimon foxChristine regan lindenboomJosh brodskyAlnylam pharmaceuticalsAlnylam pharmaceuticals nasdaqJournal of the american college cardiologyZilebesiran program lead at alnylamHeart failure programSecurities exchangeAlnylam pharmaceuticals incHealth promotion seriesExchange commissionAcceptable safety profile supporting further developmentWorld health organization

Alnylam Pharma (ALNY) Announces Publication of Phase 1 Study Results for Zilebesiran

Alnylam Pharma (ALNY) Announces Publication of Phase 1 Study Results for Zilebesiran
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomAkshay desaiSimon foxChristine regan lindenboomJosh brodskyWorld health organizationHeart failure programSecurities exchangeHealth promotion seriesAlnylam pharmaceuticals incExchange commissionAlnylam pharmaceuticalsAlnylam pharmaceuticals nasdaqZilebesiran program lead at alnylamJournal of the american college cardiologyNew england journal

Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine

Dose-Dependent Reductions in Serum Angiotensinogen and 24-hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran Acceptable Safety Profile Supporting Further Development

United kingdomSimon foxAkshay desaiAlnylam pharmaceuticalsAlnylam pharmaceuticals nasdaqZilebesiran program lead at alnylamJournal of the american college cardiologySecurities exchangeHeart failure programAlnylam pharmaceuticals incHealth promotion seriesExchange commissionWorld health organizationNew england journalTherapeutic agentAdvanced heart disease section

Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine

CAMBRIDGE, Mass. (BUSINESS WIRE) Jul 19, 2023

United kingdomUnited statesJosh brodskySimon foxAkshay desaiAlnylam pharmaceuticals nasdaqExchange commissionAlnylam pharmaceuticals inc christine regan lindenboomAlnylam pharmaceuticalsZilebesiran program lead at alnylamWorld health organizationJournal of the american college cardiologySecurities exchangeHealth promotion seriesHeart failure programAlnylam pharmaceuticals inc

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer s Disease and Cerebral Amyloid Angiopathy | Region

CAMBRIDGE, Mass. (BUSINESS WIRE) Jul 17, 2023

United kingdomUnited statesNoord hollandSharon cohenJosh brodskyTim mooneyChristine regan lindenboomExchange commissionSecurities exchangeRegeneron pharmaceuticalsAlzheimer association international conferenceAlnylam pharmaceuticalsAlnylam pharmaceuticals nasdaqProgram leader at alnylamAlnylam pharmaceuticals incToronto memory program